Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Hold” from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have received a consensus recommendation of “Hold” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $8.00.

Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Wells Fargo & Company raised their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th.

Insider Transactions at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 133,054 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $308,685.28. Following the sale, the chief executive officer directly owned 450,667 shares of the company’s stock, valued at $1,045,547.44. The trade was a 22.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Bharucha sold 58,007 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the transaction, the insider owned 91,993 shares of the company’s stock, valued at approximately $213,423.76. This trade represents a 38.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 416,327 shares of company stock worth $935,458. 19.50% of the stock is owned by corporate insiders.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIST. Sapient Capital LLC acquired a new position in Milestone Pharmaceuticals during the 3rd quarter worth about $25,000. Strategic Family Wealth Counselors L.L.C. bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth about $25,000. Eaton Financial Holdings Company LLC acquired a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth approximately $26,000. Bank of America Corp DE boosted its holdings in Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares during the last quarter. Finally, Stephenson & Company Inc. bought a new stake in Milestone Pharmaceuticals in the third quarter valued at approximately $40,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.65 on Thursday. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $3.06. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The stock’s 50-day simple moving average is $1.89 and its 200 day simple moving average is $2.00. The firm has a market capitalization of $140.53 million, a PE ratio of -2.01 and a beta of 0.48.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.